Screener Summaries Updates Institutions Sign In More Updates › Other Events › LBRX Other Events · Jul 22, 2026
LB Pharmaceuticals Inc announced an accelerated timeline for topline results from its Phase 3 NOVA-2 clinical trial of… LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc announced an accelerated timeline for topline results from its Phase 3 NOVA-2 clinical trial of LB-102 for schizophrenia, now expecting to report results in the first half of 2027 instead of the second half of 2027. The company also expects to schedule a pre-NDA meeting with the FDA in the second half of 2027. LB Pharmaceuticals is a neuromedicines company focused on developing therapies for brain diseases.
More from LB Pharmaceuticals Inc LB Pharmaceuticals completes $150M private placement and reports Q3 net loss of $59.1 million Nov 5, 2026 LB Pharmaceuticals Inc appointed Susan G. Kozauer, M.D., as Chief Medical Officer effective September 14, 2026 Sep 15, 2026 LB Pharmaceuticals Inc announced the appointment of Joseph M. Miller as its new Chief Financial Officer, effective… Sep 3, 2026 LB Pharmaceuticals Inc reported a net loss of $51.6 million for the quarter ended June 30, 2026, driven by a surge in… Aug 11, 2026 LB Pharmaceuticals Inc entered into a Securities Purchase Agreement on July 28, 2026, to raise approximately $150… Jul 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
